mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2022-5-82-87mrj-1351Research ArticleОБЗОРЫREVIEWSОбщность патогенетических аспектов, аутоиммунитета и фармакотерапии при коронавирусной инфекции (COVID-19) и иммуновоспалительных ревматических заболеванияхShared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseaseshttps://orcid.org/0000-0002-9324-8720Руцкая-МорошанК. С.Rutskaya-MoroshanK. S.

Кристина Станиславовна Руцкая-Морошан

Казахстан, 010000, Нур-Султан, ул. Бейбитшилик, 49А

Kristina S. Rutskaya-Moroshan

49A, Beibitshilik Street, Nur-Sultan 010000, Kazakhstan

rutskayakristina@gmail.comhttps://orcid.org/0000-0001-6260-8220АбишеваС. Т.AbishevaS. T.

Казахстан, 010000, Нур-Султан, ул. Бейбитшилик, 49А

49A, Beibitshilik Street, Nur-Sultan 010000, Kazakhstan

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А;

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Departmentof Rheumatology Russian Medical Academy of Continuing Professional Education

34A, Kashirskoe Shosse, Moscow 115522,

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

НАО «Медицинский университет Астана»РоссияAstana Medical UniversityRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationRussian Federation2022191020221658287Copyright © Руцкая-Морошан К.С., Абишева С.Т., Лила А.М., 20222022Руцкая-Морошан К.С., Абишева С.Т., Лила А.М.Rutskaya-Moroshan K.S., Abisheva S.T., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1351

 Обзор посвящен взаимосвязи патогенетических механизмов коронавирусной инфекции (COVID-19) и иммуновоспалительных ревматических заболеваний (ИВРЗ). Обобщены современные знания о патогенезе COVID-19, в том числе общие с ИВРЗ механизмы коагулопатии, гиперпродукции провоспалительных цитокинов, антифосфолиипидных антител. Проанализированы наличие и клиническая значимость выявления различных аутоантител при COVID-19, которые, вероятно, играют патогенетическую роль в нарушении регуляции иммунитета. На основании данных последних исследований рассматриваются факторы риска и особенности тяжелого течения инфекции у пациентов с ИВРЗ.

The review is devoted to the relationship between the pathogenetic mechanisms of coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases (IRD). The current knowledge on the pathogenesis of COVID-19 is summarized, including the mechanisms of coagulopathy, hyperproduction of pro-inflammatory cytokines, and antiphospholipid antibodies that are common with IRD. The presence and clinical significance of detection of various autoantibodies in COVID-19, which probably play a pathogenetic role in immune dysregulation, were analyzed. Based on the data of recent studies, risk factors and features of the severe course of infection in patients with IRD are considered.

COVID-19иммуновоспалительные ревматические заболеванияфакторы рискааутоантителапротиворевматические препаратыCOVID-19immunoinflammatory rheumatic diseasesrisk factorsautoantibodiesantirheumatic drugsReferencesTentolouris A, Ntanasis-Stathopoulos I, Vlachakis PK, et al. COVID-19: time to flatten the infodemic curve. Clin Exp Med. 2021 May;21(2):161-5. doi: 10.1007/s10238-020-00680-x. Epub 2021 Jan 8.Tentolouris A, Ntanasis-Stathopoulos I, Vlachakis PK, et al. COVID-19: time to flatten the infodemic curve. Clin Exp Med. 2021 May;21(2):161-5. doi: 10.1007/s10238-020-00680-x. Epub 2021 Jan 8.Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021; 59(1):5-30.Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchnoprakticheskaya revmatologiya. 2021;59(1): 5-30. (In Russ.).Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): вклад ревматологии. Терапевтический архив. 2021;(5):537–50.Nasonov EL. Coronavirus disease 2019 (COVID-19): contribution of rheumatology. Terapevticheskii Arkhiv. 2021;(5):537–50. (In Russ.).Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631-7. doi: 10.1002/path.1570.Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631-7. doi: 10.1002/path.1570.Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021 May; 97(1147):312-20. doi: 10.1136/postgradmedj-2020-138577.Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021 May; 97(1147):312-20. doi: 10.1136/postgradmedj-2020-138577.Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.Weatherhead JE, Clark E, Vogel TP, et al. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. J Clin Invest. 2020 Dec 1;130(12):6194-7. doi: 10.1172/JCI145301.Weatherhead JE, Clark E, Vogel TP, et al. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. J Clin Invest. 2020 Dec 1;130(12):6194-7. doi: 10.1172/JCI145301.Triggle CR, Bansal D, Ding H, et al. A ComprehensiveReview of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Managementof SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol. 2021 Feb 26;12: 631139. doi: 10.3389/fimmu.2021.631139. eCollection 2021.Triggle CR, Bansal D, Ding H, et al. A ComprehensiveReview of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Managementof SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol. 2021 Feb 26;12: 631139. doi: 10.3389/fimmu.2021.631139. eCollection 2021.Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология 2020;58(4):353-67.Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated (autoimmune) inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologiya. 2020; 58 (4):353-67. (In Russ.).Merrill JT, Erkan D, Winakur J, et al. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020 Oct;16(10):581-9. doi: 10.1038/s41584-020-0474-5. Epub 2020 Jul 30.Merrill JT, Erkan D, Winakur J, et al. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020 Oct;16(10):581-9. doi: 10.1038/s41584-020-0474-5. Epub 2020 Jul 30.Gu SX, Tyagi T, Jain K, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021 Mar;18(3):194-209. doi: 10.1038/s41569-020-00469-1. Epub 2020 Nov 19.Gu SX, Tyagi T, Jain K, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021 Mar;18(3):194-209. doi: 10.1038/s41569-020-00469-1. Epub 2020 Nov 19.Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020 Jun 1;217(6):e20200652. doi: 10.1084/jem.20200652.Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020 Jun 1;217(6):e20200652. doi: 10.1084/jem.20200652.Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellulartraps in rheumatic diseases. Nat Rev Rheumatol. 2018 Aug;14(8): 467-75. doi: 10.1038/s41584-018-0039-z.Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellulartraps in rheumatic diseases. Nat Rev Rheumatol. 2018 Aug;14(8): 467-75. doi: 10.1038/s41584-018-0039-z.Zuo Y, Yalavarthi S, Shi H, et al. Neutrophilextracellular traps in COVID-19. JCI Insight. 2020 Jun 4;5(11):e138999. doi: 10.1172/jci.insight.138999.Zuo Y, Yalavarthi S, Shi H, et al. Neutrophilextracellular traps in COVID-19. JCI Insight. 2020 Jun 4;5(11):e138999. doi: 10.1172/jci.insight.138999.Zuo Y, Zuo M, Yalavarthi S, et al. Neutrophil extracellular traps and thrombosis in COVID-19. Neutrophil extracellular traps in COVID-19. MedRxiv. 2020 May 5;2020.04.30. 20086736. doi: 10.1101/2020.04.30.20086736. PreprintZuo Y, Zuo M, Yalavarthi S, et al. Neutrophil extracellular traps and thrombosis in COVID-19. Neutrophil extracellular traps in COVID-19. MedRxiv. 2020 May 5;2020.04.30. 20086736. doi: 10.1101/2020.04.30.20086736. PreprintMeroni PL, Borghi MO, Raschi E, et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011 Jun;7(6):330-9. doi: 10.1038/nrrheum.2011.52. Epub 2011 May 10.Meroni PL, Borghi MO, Raschi E, et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011 Jun;7(6):330-9. doi: 10.1038/nrrheum.2011.52. Epub 2011 May 10.Bertin D, Brodovitch A, Beziane A, et al. Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID-19 Severity. Arthritis Rheumatol. 2020 Nov;72(11): 1953-5. doi: 10.1002/art.41409. Epub 2020 Sep 22.Bertin D, Brodovitch A, Beziane A, et al. Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID-19 Severity. Arthritis Rheumatol. 2020 Nov;72(11): 1953-5. doi: 10.1002/art.41409. Epub 2020 Sep 22.Zuo Y, Estes K, Ali R, et al. Prothrombotic antiphospholipid antibodies in COVID-19. МedRxiv. 2020 Sep 15; 2020.06.15.20131607 doi: 10.1101/2020.06.15.20131607. PreprintZuo Y, Estes K, Ali R, et al. Prothrombotic antiphospholipid antibodies in COVID-19. МedRxiv. 2020 Sep 15; 2020.06.15.20131607 doi: 10.1101/2020.06.15.20131607. PreprintTrahtemberg U, Rottapel R, Dos Santos CC, et al. Anticardiolipin and other antiphospholipid antibodiesin critically ill COVID-19 positive and negative patients. Ann Rheum Dis. 2021 Sep;80(9):1236-40. doi: 10.1136/annrheumdis-2021-220206. Epub 2021 Apr 26.Trahtemberg U, Rottapel R, Dos Santos CC, et al. Anticardiolipin and other antiphospholipid antibodiesin critically ill COVID-19 positive and negative patients. Ann Rheum Dis. 2021 Sep;80(9):1236-40. doi: 10.1136/annrheumdis-2021-220206. Epub 2021 Apr 26.Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021 May;7(2): e001580. doi: 10.1136/rmdopen-2021-001580.Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021 May;7(2): e001580. doi: 10.1136/rmdopen-2021-001580.Abdel-Wahab N, Talathi S, LopezOlivo MA, et al. Risk of developing antiphospholipid antibodies followingviral infection: a systematic review and meta-analysis. Lupus. 2018 Apr;27(4):572-83. doi: 10.1177/0961203317731532. Epub 2017 Sep 24.Abdel-Wahab N, Talathi S, LopezOlivo MA, et al. Risk of developing antiphospholipid antibodies followingviral infection: a systematic review and meta-analysis. Lupus. 2018 Apr;27(4):572-83. doi: 10.1177/0961203317731532. Epub 2017 Sep 24.Didier K, Bolko L, Giusti D, et al. Autoantibodies associated with connective tissue diseases:What meaning for clinicians? Front Immunol. 2018 Mar 26;9:541. doi: 10.3389/fimmu.2018.00541. eCollection 2018.Didier K, Bolko L, Giusti D, et al. Autoantibodies associated with connective tissue diseases:What meaning for clinicians? Front Immunol. 2018 Mar 26;9:541. doi: 10.3389/fimmu.2018.00541. eCollection 2018.Sener AG, Afsar I, Demirci M. Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods': four years' data from Turkey. APMIS. 2014 Dec;122(12):1167-70. doi: 10.1111/apm.12275. Epub 2014 Apr 16.Sener AG, Afsar I, Demirci M. Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods': four years' data from Turkey. APMIS. 2014 Dec;122(12):1167-70. doi: 10.1111/apm.12275. Epub 2014 Apr 16.Damoiseaux J, von Mühlen CA, GarciaDe La Torre I, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016 Dec;7(1):1. doi: 10.1007/s13317-016-0075-0. Epub 2016 Jan 30.Damoiseaux J, von Mühlen CA, GarciaDe La Torre I, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016 Dec;7(1):1. doi: 10.1007/s13317-016-0075-0. Epub 2016 Jan 30.Gao ZW, Zhang HZ, Liu C, Dong K. Autoantibodies in COVID-19: frequency and function. Autoimmun Rev. 2021 Mar;20(3): 102754. doi: 10.1016/j.autrev.2021.102754.Gao ZW, Zhang HZ, Liu C, Dong K. Autoantibodies in COVID-19: frequency and function. Autoimmun Rev. 2021 Mar;20(3): 102754. doi: 10.1016/j.autrev.2021.102754.Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020 Dec;79(12):1661-3. doi: 10.1136/annrheumdis-2020-218009. Epub 2020 Jun 24.Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020 Dec;79(12):1661-3. doi: 10.1136/annrheumdis-2020-218009. Epub 2020 Jun 24.Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021 Mar;14(2):502-8. doi: 10.1111/cts.12908. Epub 2021 Jan 20.Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021 Mar;14(2):502-8. doi: 10.1111/cts.12908. Epub 2021 Jan 20.Lerma LA, Chaudhary A, Bryan A, et al. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020;3:100073. doi: 10.1016/j.jtauto.2020.100073. Epub 2020 Nov 27.Lerma LA, Chaudhary A, Bryan A, et al. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020;3:100073. doi: 10.1016/j.jtauto.2020.100073. Epub 2020 Nov 27.Buvry C, Cassagnes L, Tekath M, et al. Anti-Ro52 antibodies are a risk factor for interstitial lung diseasein primary Sjogren syndrome. Respir Med. 2020 Mar;163:105895. doi: 10.1016/j.rmed.2020.105895. Epub 2020 Feb 7.Buvry C, Cassagnes L, Tekath M, et al. Anti-Ro52 antibodies are a risk factor for interstitial lung diseasein primary Sjogren syndrome. Respir Med. 2020 Mar;163:105895. doi: 10.1016/j.rmed.2020.105895. Epub 2020 Feb 7.Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Childhood Myositis Heterogeneity Collaborative Study Group. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019 Jul; 78(7):988-95. doi: 10.1136/annrheumdis2018-215004. Epub 2019 Apr 24.Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Childhood Myositis Heterogeneity Collaborative Study Group. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019 Jul; 78(7):988-95. doi: 10.1136/annrheumdis2018-215004. Epub 2019 Apr 24.Cappelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015 Sep;24(137):411-9. doi: 10.1183/16000617.00002915.Cappelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015 Sep;24(137):411-9. doi: 10.1183/16000617.00002915.Varga J. Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma). https://www.uptodate.com/contents/clinicalmanifestations-evaluation-and-diagnosisofinterstitial-lung-disease-in-systemic-sclerosis-scleroderma.Varga J. Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma). https://www.uptodate.com/contents/clinicalmanifestations-evaluation-and-diagnosisofinterstitial-lung-disease-in-systemic-sclerosis-scleroderma.Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun; 79(6):760-70. doi: 10.1136/annrheumdis2019-216653. Epub 2020 Feb 7.Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun; 79(6):760-70. doi: 10.1136/annrheumdis2019-216653. Epub 2020 Feb 7.Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-6. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-6. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol. 2020 Sep;2(9):e557-e564. doi: 10.1016/S2665-9913(20)30227-7. Epub 2020 Jul 3.Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol. 2020 Sep;2(9):e557-e564. doi: 10.1016/S2665-9913(20)30227-7. Epub 2020 Jul 3.Gu T, Mack JA, Salvatore M, et al. COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine. medRxiv. 2020 Jun 18;2020.06.16.20133140. doi: 10.1101/2020.06.16.20133140. PreprintGu T, Mack JA, Salvatore M, et al. COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine. medRxiv. 2020 Jun 18;2020.06.16.20133140. doi: 10.1101/2020.06.16.20133140. PreprintSalvarani C, Bajocchi G, Mancuso P, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 Jul;79(7):986-8. doi: 10.1136/annrheumdis-2020-217903. Epub 2020 May 28.Salvarani C, Bajocchi G, Mancuso P, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 Jul;79(7):986-8. doi: 10.1136/annrheumdis-2020-217903. Epub 2020 May 28.Pablos JL, Abasolo-Alcazar L, AlvaroGracia JM, et al. Prevalence of hospital PCRconfirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020 Sep; 79(9):1170-3. doi: 10.1136/annrheumdis2020-217763. Epub 2020 Jun 12.Pablos JL, Abasolo-Alcazar L, AlvaroGracia JM, et al. Prevalence of hospital PCRconfirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020 Sep; 79(9):1170-3. doi: 10.1136/annrheumdis2020-217763. Epub 2020 Jun 12.Shin YH, Shin JI, Moon SY, et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021 Oct;3(10):e698-e706. doi: 10.1016/S2665-9913(21)00151-X.Shin YH, Shin JI, Moon SY, et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021 Oct;3(10):e698-e706. doi: 10.1016/S2665-9913(21)00151-X.Gupta R, Misra A. COVID19 in South Asians/Asian Indians: Heterogeneity of data and implications for pathophysiology and research. Diabetes Res Clin Pract. 2020 Jul;165: 108267.Gupta R, Misra A. COVID19 in South Asians/Asian Indians: Heterogeneity of data and implications for pathophysiology and research. Diabetes Res Clin Pract. 2020 Jul;165: 108267.Sagnella GA, Rothwell MJ, Onipinla AK, et al. A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism. J Hypertens. 1999 May;17(5):657-64. doi: 10.1097/00004872-199917050-00009.Sagnella GA, Rothwell MJ, Onipinla AK, et al. A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism. J Hypertens. 1999 May;17(5):657-64. doi: 10.1097/00004872-199917050-00009.Francesconi P, Cantini F, Profili F, et al. COVID-19 epidemiology in rheumatic diseases in Tuscany: a case- control study. Joint Bone Spine. 2021 May;88(3):105131. doi: 10.1016/j.jbspin.2021.105131. Epub 2021 Jan 21.Francesconi P, Cantini F, Profili F, et al. COVID-19 epidemiology in rheumatic diseases in Tuscany: a case- control study. Joint Bone Spine. 2021 May;88(3):105131. doi: 10.1016/j.jbspin.2021.105131. Epub 2021 Jan 21.Topless RK, Phipps-Green А, Leask М, et al. Gout, rheumatoid arthritis, and the risk of death related to coronavirus disease 2019: an analysis of the UK Biobank. ACR Open Rheumatol. 2021 May; 3(5):333-40. doi: 10.1002/acr2.11252. Epub 2021 Apr 15.Topless RK, Phipps-Green А, Leask М, et al. Gout, rheumatoid arthritis, and the risk of death related to coronavirus disease 2019: an analysis of the UK Biobank. ACR Open Rheumatol. 2021 May; 3(5):333-40. doi: 10.1002/acr2.11252. Epub 2021 Apr 15.England BR, Roul P, Yang Y, et al. Risk of COVID-19 in rheumatoid arthritis: a National Veterans Affairs matched cohort study in atrisk individuals. Arthritis Rheumatol. 2021 Dec;73(12):2179-88. doi: 10.1002/art.41800. Epub 2021 Oct 19.England BR, Roul P, Yang Y, et al. Risk of COVID-19 in rheumatoid arthritis: a National Veterans Affairs matched cohort study in atrisk individuals. Arthritis Rheumatol. 2021 Dec;73(12):2179-88. doi: 10.1002/art.41800. Epub 2021 Oct 19.Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020 Jul 1;202(1):83-90. doi: 10.1164/rccm.202003-0821OC.Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020 Jul 1;202(1):83-90. doi: 10.1164/rccm.202003-0821OC.Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2021 Feb;147(2):510-9.e5. doi: 10.1016/j.jaci.2020.09.034. Epub 2020 Oct 15.Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2021 Feb;147(2):510-9.e5. doi: 10.1016/j.jaci.2020.09.034. Epub 2020 Oct 15.Reilev M, Kristensen KB, Pottegеrd A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020 Oct 1;49(5):1468-81. doi: 10.1093/ije/dyaa140.Reilev M, Kristensen KB, Pottegеrd A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020 Oct 1;49(5):1468-81. doi: 10.1093/ije/dyaa140.Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-6. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-6. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS Med. 2020 Sep 10; 17(9):e1003321. doi: 10.1371/journal.pmed.1003321. eCollection 2020 Sep.Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS Med. 2020 Sep 10; 17(9):e1003321. doi: 10.1371/journal.pmed.1003321. eCollection 2020 Sep.D’Silva KM, Jorge A, Cohen A, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol. 2021 Jun;73(6):914-20. doi: 10.1002/art.41619. Epub 2021 May 1.D’Silva KM, Jorge A, Cohen A, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol. 2021 Jun;73(6):914-20. doi: 10.1002/art.41619. Epub 2021 May 1.Conway R, Grimshaw AA, Konig MF, et al. COVID-19 Global Rheumatology Alliance. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis. Arthritis Rheumatol. 2021 Nov 22; doi: 10.1002/art.42030.Conway R, Grimshaw AA, Konig MF, et al. COVID-19 Global Rheumatology Alliance. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis. Arthritis Rheumatol. 2021 Nov 22; doi: 10.1002/art.42030.Liew JW, Bhana S, Costello W, et al. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology (Oxford). 2021 Jan 5; 60(1):353-8. doi: 10.1093/rheumatology/keaa483.Liew JW, Bhana S, Costello W, et al. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology (Oxford). 2021 Jan 5; 60(1):353-8. doi: 10.1093/rheumatology/keaa483.Wallace ZS, Bhana S , Hausmann JS, et al. The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology (Oxford). 2020 Jun 1;59(6): 1204-6. doi: 10.1093/rheumatology/keaa191.Wallace ZS, Bhana S , Hausmann JS, et al. The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology (Oxford). 2020 Jun 1;59(6): 1204-6. doi: 10.1093/rheumatology/keaa191.Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol. 2020 Jun;16(6):293-4. doi: 10.1038/s41584-020-0418-0.Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol. 2020 Jun;16(6):293-4. doi: 10.1038/s41584-020-0418-0.Strangfeld A, Schefer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician- reported registry. Ann Rheum Dis. 2021 Jul;80(7): 930-42. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.Strangfeld A, Schefer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician- reported registry. Ann Rheum Dis. 2021 Jul;80(7): 930-42. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.Machado PM, Schefer M, Gossec L, et al. Response to: “Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physicianreported registry’” . Ann Rheum Dis. 2021 Mar 1;annrheumdis-2021-220134. doi: 10.1136/annrheumdis-2021-220134. Online ahead of print.Machado PM, Schefer M, Gossec L, et al. Response to: “Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physicianreported registry’” . Ann Rheum Dis. 2021 Mar 1;annrheumdis-2021-220134. doi: 10.1136/annrheumdis-2021-220134. Online ahead of print.Robinson PC, Morand E. Divergent effects of acute versus chronic glucocorticoids in COVID-19. Lancet Rheumatol. 2021 Mar; 3(3):e168-e170. doi: 10.1016/S2665-9913(21)00005-9. Epub 2021 Jan 18.Robinson PC, Morand E. Divergent effects of acute versus chronic glucocorticoids in COVID-19. Lancet Rheumatol. 2021 Mar; 3(3):e168-e170. doi: 10.1016/S2665-9913(21)00005-9. Epub 2021 Jan 18.Brightling C, Ustianowski A, Elmahi E, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8): 693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.Brightling C, Ustianowski A, Elmahi E, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8): 693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639.Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639.

The authors declare that there are no conflicts of interest present.